This record was last updated November 18, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase II randomised, open-label study to assess the safety and immunogenicity of coadministration of the candidate rabies vaccine ChAdOx2 RabG and licensed vaccine in healthy adults (18-45 years old). ChAdOx2 RabG will be administered intramuscularly and licensed rabies vaccine will be given either intramuscularly (i.e., for the intervention group) or by intradermal injection (i.e., for the control group).
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-04; most recent amendment 2025-11-14.